Background Surrogate endpoints potentially reduce the duration and/or increase the amount of information available in a study, thereby diminishing patient burden and cost. They may also increase the effectiveness and reliability of research, through beneficial impact on noncompliance and missingness. Purpose In this article, we review the meta-analytic approach of Buyse et al. (2000) and its extension to mixed continuous and binary endpoints by Molenberghs Geys, and Buyse (2001). Methods An information-theoretic alternative, based on Alonso and Molenberghs (2007a) is proposed. The method is evaluated using simulations and application to data from an ophthalmologic trial, with lines of vision lost at 6 months as candidate surrogate endpoints for lines of vision lost at 12 months. The method is implemented as an R function. Results The information-theoretic approach is based on solid theory, easy to apply, and enjoys elegant properties. While the information-theoretic approach appears to be somewhat biased downwards, this is due to fact that it operates at explicitly observed outcomes, without the need for unobserved, latent scales. This is a desirable property. Limitations While easy-to-use and implement, the theoretical foundation of the information-theory approach is more mathematical. It produces some bias for small to moderate trial/center sizes, and hence is recommended primarily for sufficiently large trials. Conclusions Since the meta-analytic framework can be computationally extremely expensive, the information-theoretic approach of Alonso and Molenberghs (2007a) is a viable alternative. For the ophthalmologic case study, the conclusion is that the lines of vision lost at sixth month do have some, but not overwhelming promise as a surrogate endpoint.
Introduction
Evaluation of new treatments (Z ) is based on the observation of clinically meaningful variables that are sensitive to detect treatment effects, which we shall refer to as the true endpoints (T ). However, such variables might increase the complexity and/ or the duration of a clinical trial, either because they are costly, difficult to measure, require a long follow-up time, or require a large sample size due to low incidence of the event. These problems might be avoided through replacing the true endpoints by other ones, measured earlier or in a more convenient fashion, termed surrogate endpoints (S; [1] ). For some chronic diseases, survival is the ultimate endpoint which clinicians would like to affect but cannot always observe due to the prolonged period of follow-up required.
Thus, intermediate endpoints must be considered, for instance, using CD4 blood count and viral load in so-called highly active antiretroviral therapies (HAART), rather than conventional clinical events and overall survival in HIV positive subjects [2] .
It is evident from the above that candidate surrogate endpoints should be associated with the true endpoint. However, an association is not sufficient for using the former as a surrogate endpoint [3] . A surrogate for a true endpoint is an endpoint that can be used in lieu of the true endpoint to assess treatment benefits. That is, the effect of the treatment on the surrogate endpoint should reliably predict the effect of the treatment on the true endpoint. Consequently, formal methods for validating or evaluating candidate surrogate endpoints are required. The following paragraph presents a brief overview of some statistical methods developed for the evaluation of surrogate endpoints. It should be noted that, although a quantitative evaluation is important, it is by no means the only component in the decision process. Several parties, such as the regulatory agencies and the industry developing a medical product, are involved [4] .
Several formal methods for evaluating surrogate endpoints have been proposed. A landmark paper by Prentice [5] proposed a formal definition of surrogate endpoints, together with a set of criteria for validating surrogate endpoints. Freedman et al. [6] and Buyse and Molenberghs [7] supplemented Prentice's proposal with the estimation paradigm, introducing measures which can be used to evaluate surrogate endpoints. The above proposals are all based on a single trial, thus, the lack of replication at the treatment level hampers inferences about the prediction of treatment effect on the true endpoint based on its effect on the surrogate. This led to the proposal of a meta-analytic approach by several authors, e.g. Albert et al. [8] , Daniels and Hughes [9] using a Bayesian approach, Buyse et al. [10] and Gail et al. [11] , using the theory of linear mixed-effects models and related hierarchical modeling frameworks. This article is situated within the philosophy of Buyse et al. [10] .
The meta-analytic approach proposed by Buyse et al. [10] has been formulated originally for two continuous, normally distributed outcomes. It has been extended to handle mixed continuous and binary endpoints by Molenberghs et al. [12] , as well as other sets of outcome types. A review can be found in Burzykowski et al. [13] . In this article, we review an extension to mixed continuous and binary outcomes, together with validation based on a so-called Information-theoretic Approach (ITA), introduced by Alonso and Molenberghs [14] . This article, provides the first application of ITA to the mixed continuous-discrete case, in contrast to Tilahun et al. [15, 16] , who studied homogeneous continuous endpoints and homogeneous binary endpoints, respectively, and Alonso and Molenberghs [17] , who focused on time-to-event endpoints.
Data from a motivating clinical trial are introduced in section 'The age-related macular degeneration study'. Section 'Validation methods' reviews the meta-analytic approach and the extensions needed in this article. The case study is analyzed in section 'Analysis of the ARMD data'. A simulation study is undertaken to investigate the performance of ITA, as well as the operational characteristics of various ways to derive confidence interval for measures of surrogacy. Also, the assumption of linearity, inherent in the models, is put to the test. The simulation study is reported in section 'A simulation study'. Calculations are based on a generic R function, written by the first author. Details of the function are given in the Appendix; the interested reader can download the function from the authors' web site.
The age-related macular degeneration study (ARMD)
The mixed continuous-binary case is encountered in data from a randomized multi-center clinical trial, involving patients with age-related macular degeneration, a condition in which patients progressively lose vision. Overall, 190 patients from 42 centers participated in the trial. Patients' visual acuity was assessed using standardized vision charts displaying lines of five letters of decreasing size, which patients had to read from top to bottom. The visual acuity was measured by the number of letters correctly read. Each line with at least four letters correctly read is called one 'line of vision'. The surrogate endpoint S is the binary variable indicating the loss of at least two lines of vision at 6 months while the true endpoint T is the change in visual acuity at 1 year. The binary indicator for treatment is set to Z ¼ À1 for placebo and Z ¼ 1 for interferon-. In the analysis, the centers in which patients were treated will be considered as units of analysis. Six out of 42 centers participating in the trial enrolled patients only to one of the two treatment arms. These centers were excluded from further consideration. A total of 36 centers were thus available for analysis, with a number of individual patients per center ranging from 2 to 18 (183 patients overall). Note that these numbers are relatively small and, ideally, validation ought to be based on sufficiently large centers/trials. Evidently, data ought to be available and it is here were biopharmaceutical companies and other trial sponsors could contribute through data sharing.
Validation methods
We first briefly review the meta-analytic framework in the case of two normally distributed endpoints, and then move on to its extension to the case of mixed binary continuous endpoints. In view of the computational demands placed on fitting the models, evaluation of surrogate endpoints using ITA is presented as an attainable alternative.
Two normally distributed endpoints
As it is the basis for what follows, it is useful to briefly review the random-effects model used by Buyse et al. [10] for surrogate endpoint validation in multiple randomized trials in the case of two normally distributed endpoints. We refer to this paper for additional details. It rests upon a joint regression model for S and T:
where i ¼ 1; . . . ; N refers to the trials and j ¼ 1; . . . ; n i to the subjects within trials. Parameters S and T are fixed intercepts, and are the fixed effects of treatment Z on the endpoints, m Si and m Ti are random intercepts, and a i and b i are the random effects of treatment Z on the endpoints in trial i. The vector of random effects (m Si , m Ti , a i , b i ) is assumed to be mean-zero normally distributed with covariance matrix
The error terms " Sij and " Tij are correlated and assumed to be mean-zero normally distributed with covariance matrix
A measure to assess the quality of a surrogate at the trial level is given by the coefficient of determination
This coefficient measures how precise the effect of treatment on the true endpoint can been predicted if the treatment effect on the surrogate has been observed in a new trial. It is unitless and ranges in the unit interval if D is positive definite, two desirable features for its interpretation. A measure to assess the quality of surrogate at the individual level is given by the coefficient of determination
which is the squared correlation between S and T after adjusting for the treatment and trial effects. A surrogate endpoint is valid if it is both trial-level valid ðR 2 trial % 1Þ and individual level valid ðR 2 indiv % 1Þ. Expert opinion and confidence limits may help in determining how close these values should be close to 1. As mentioned before in 'Introduction' section, these statistical measures should be complimented with decisions from a regulatory agency and other parties, when deciding whether an endpoint is an appropriate surrogate for a true endpoint.
Although the meta-analytic approach is theoretically appealing, it faces some practical computational problems. This is especially true in situations with extreme correlation and/or when the number of trials or number of patients per trial is small. Tibaldi et al. [18] circumvented this issue by introducing a number of simplified modeling strategies that are less computationally demanding. Tilahun et al. [15] highlighted some computational issues and further illustrated these through a simulation study. They also presented SAS macros and R functions for the implementation of both the meta-analytic approach and the simplified strategies, for normally distributed endpoints. Tilahun et al. [17] study the metaanalytic framework and the information-theoretic approach in the situation that both the surrogate and the true endpoint are binary. Alonso and Molenberghs [17] deal with a pair of endpoints that are of a time-to-event nature. However, a quite different situation arises when the surrogate endpoint is continuous and the true endpoint is binary, or vice versa, a so-called heterogeneous situation. This is the topic of the current manuscript.
Methods for combined binary and normally distributed endpoints
Statistical problem where various outcomes of a combined nature are observed are common, especially with normally distributed outcomes on the one hand and binary or categorical outcomes on the other hand. Emphasis may be on the determination of the entire joint distribution of both outcomes or on specific aspects, such as the association in general or correlation in particular between both outcomes. Burzykowski, et al. [13] review extensions of the meta-analytic approach, ranging over continuous, binary, ordinal, timeto-event, and longitudinally measured outcomes. Here, we focus on the combination of continuous and binary outcomes.
In this section, we start with a bivariate nonhierarchical setting, which can always be expressed as the product of a marginal distribution of one of the responses and the conditional distribution of the remaining response given the former one. The main problem with this approach is that no easy expressions for the association between both endpoints are available. Thus, we opt for a symmetric treatment of both endpoints. We focus on the case where the true endpoint is continuous and the surrogate is binary, the reverse case being entirely similar.
Generalized linear mixed models for endpoints of different data types are challenging [19] . Hence, we concentrate on two-stage fixed-effects models. In the first stage, let S ij be a latent variable of which S ij is the dichotomized version. A bivariate normal model for S ij and T ij is given by [12] :
where Si and Ti are trial-specific intercepts, i and i are trial-specific effects of treatment Z ij on the endpoints in trial i, and " Si and " Ti are correlated error terms, assumed to be zero-mean normally distributed with covariance matrix
The variance of S ij is chosen for computational reasons. Using a probit formulation like
Molenberghs et al. [12] and owing to the replication at the trial level, we can impose a distribution on the trial-specific parameters. At the second stage, we assume
where the second term on the right hand of (10) is assumed to follow a zero-mean normal distribution with dispersion matrix (3) . Measures to assess the quality of the surrogate both at the trial and individual level are obtained as in (5) and (6). Interpretation of these measures and decision making follows the logic laid out in section 'Two normally distributed endpoints'.
A unified approach
The meta-analytic framework requires different hierarchical models for different types of outcomes. First using the likelihood reduction factor (section 'The likelihood reduction factor') and then an information-theoretic approach (section 'An information-theoretic unification'), extension, and therefore unification, will be achieved, in line with Alonso and Molenberghs [14] .
The likelihood reduction factor
Estimating individual-level surrogacy, as the previous developments clearly show, has frequently been based on a variance-covariance matrix coming from the distribution of the residuals. However, if we move away from the normal distribution, it is not always clear how to quantify the association between both endpoints after adjusting for treatment and trial effect. To address this problem, Alonso et al. [20] and Alonso and Molenberghs [14, 17] considered the following generalized linear models
where g T is an appropriate link function, Ti are the trial-specific intercepts and i are trial-specific effects of treatment Z on the true endpoint in trial i. 0i and 1i are trial-specific intercepts and effects of treatment on the true endpoint when the surrogate endpoint is known. Note that (11) and (12) can be readily extended to incorporate more complex settings. Other extensions, such as nonlinearity between S ij and g T fEðT ij Þg are possible. We assume a linear relationship between S ij and g T fEðT ij Þg, but consider extensions of (11) and (12) in the light of simplified modeling strategy, as presented by Tibaldi et al. [18] . They suggested several simplifications for the case of continuous true and surrogate endpoints. They have introduced the concept of three possible dimensions along which simplifications can be made: the trial, endpoint, and measurement error dimensions. Their ideas can be applied outside the original linear mixed model-based framework, too. We consider their trial and measurement error dimensions.
The trial dimension provides a choice between treating the trial-specific effects as fixed or random. The former is often chosen out of necessity, when the latter is too challenging. If the trial-specific effects are chosen fixed, then (11) and (12) are used to validate the surrogate endpoint. On the other hand, if the trial-specific effects are considered random, we extend (11) and (12) to appropriate generalized linear mixed-effects models
where T and are a fixed intercept and treatment effect on the true endpoint, while m Ti and b i are a random intercept and treatment effects on the true endpoint. 0 and 1 are a fixed intercept and treatment effect on the true endpoint when the surrogate is known, and c Ti and a i are a random intercept and treatment effects on the true endpoint when the surrogate is known.
It is often the case in practice that different trials in meta-analysis have different sizes. Since univariate models are used to evaluate surrogacy in the information-theoretic approach, there is a need to adjust for the heterogeneity in information content between trial-specific contributions. This is the target of the choices along the so-called measurement error dimension. One way to account for a variable amount of information per trial is by weighting the contributions according to trial size, thus giving rise to a weighted linear regression models, particularly when estimating measures for trial-level surrogacy.
Let us turn to the so-called likelihood reduction factor (LRF). Observe that, in the case where the true endpoint is continuous and normally distributed, (11) and (12) reduce to normal regression models and (13) and (14) reduce to linear mixed models. On the other hand, when the true endpoint is binary, (11) and (12) reduce to logistic regression models. Alonso and Molenberghs (2007) used the LRF to evaluate individual level surrogacy, which is obtained by
where G 2 i denotes the log-likelihood ratio test statistic to compare (11) and (12) or (13) and (14) within trial i. Alonso et al. [20] established a number of properties for LRF, in particular its ranging in the unit interval and, importantly, its reduction to R 2 ind in the cross-sectional case.
An information-theoretic unification
This proposal avoids the needs for a joint, hierarchical model, and allows for unification across different types of endpoints. The entropy of a random variable [21] , a good measure of randomness or uncertainty, is defined in the following way for the case of a discrete random variable Y, taking values fk 1 ; k 2 ; . . . ; k m g, and with probability function PðY ¼ k i Þ ¼ p i :
The differential entropy h d (X) of a continuous variable X with density f X (x) and support S f X equals
The joint and conditional (differential) entropies are defined in an analogous fashion. Defining the information of a single event as IðAÞ ¼ log p A , the entropy is HðAÞ ¼ ÀIðAÞ. No information is gained from a totally certain event, p A % 1, so IðAÞ % 0), while an improbable event is informative. H(Y) is the average uncertainty associated with P. Entropy is always nonnegative, satisfies HðYjX Þ HðY Þ for any pair of random variables, with equality holding under independence, and is invariant under a bijective transformation [22] . Differential entropy enjoys some but not all properties of entropy: it can be infinitely large, negative, or positive, and is coordinate dependent. For a bijective transformation Y ¼ yðXÞ, it follows h d ðYÞ ¼ h d ðXÞ À E Y log dx=dyðyÞ À Á . We can now quantify the amount of uncertainty in Y, expected to be removed if the value of X were known, by IðX; YÞ ¼ h d ðYÞ À h d ðYjXÞ, the so-called mutual information. It is always nonnegative, zero if and only if X and Y are independent, symmetric, invariant under bijective transformations of X and Y, and IðX; XÞ ¼ h d ðXÞ. The mutual information measures the information of X, shared by Y.
We will now introduce the entropy-power [21] for comparison of continuous random variables. Let X be a continuous n-dimensional random vector. The entropy-power of X is
The differential entropy of a continuous normal random variable is hðXÞ ¼ 1 2 log 2 2 À Á , a simple function of the variance and, on the natural logarithmic scale:
In general, EPðXÞ VarðXÞ with equality if and only if X is normally distributed.
We can now define an information-theoretic measure of association (Schemper and Stare 1996):
which ranges in the unit interval, equals zero if and only if (X, Y) are independent, is symmetric, is invariant under bijective transformation of X and Y, and, when R 2 h ! 1 for continuous models, there is usually some degeneracy appearing in the distribution of (X,Y). There is a direct link between R 2 h and the mutual information: R 2 h ¼ 1 À e À2IðX;YÞ . For Y discrete: R 2 h 1 À e À2HðYÞ , implying that R 2 h then has an upper bound smaller than 1; we then redefine
reaching 1 when both endpoints are deterministically related.
We can now redefine surrogacy, while preserving previous proposals as special cases. While we will focus on individual-level surrogacy, all results apply to the trial level too. Let Y ¼ T and X ¼ S be the true and surrogate endpoints, respectively. We consider S a good surrogate for T at the individual (trial) level, if a 'large' amount of uncertainty about T (the treatment effect on T ) is reduced when S (the treatment effect on S) is known. Equivalently, we term S a good surrogate for T at the individual level, if our lack of knowledge about the true endpoint is substantially reduced when the surrogate endpoint is known.
A meta-analytic framework, with N clinical trials, produces N q different R 2 hi , and hence we propose a meta-analytic R 2 h :
where i 40 for all i and P N q i¼1 i ¼ 1. Different choices for i lead to different proposals, producing an uncountable family of parameters. This opens the additional issue of finding an optimal choice. In particular, for the cross-sectional normal-normal case, Alonso and Molenberghs [17] have shown that R 2 h ¼ R 2 ind . The same holds for R 2 Ã for the longitudinal case. Finally, when the true and surrogate endpoints have distributions in the exponential family, then LRF ! P R 2 h when the number of subjects per trial goes to infinity.
Alonso and Molenberghs [14] developed asymptotic confidence intervals for R 2 h , based on the idea of Kent [23] , to build confidence intervals for 2IðT; SÞ. Letâ ¼ 2n b IðT; SÞ, where n is the number of patients. Define k 1: (a) and 1: (a) by P 1 2 ð1 : ðaÞÞ ! a À Á ¼ and P 1 2 ð1 : ðaÞÞ a À Á ¼ . Here, 2 1 is a chi-squared random variable with 1 degree of freedom. If P 1 2 ð0Þ ! a À Á ¼ then we set 1 
where 1 À i is the Bonferroni confidence level for the trial intervals [14] . This asymptotic interval has considerable computational advantage with respect to the bootstrap approach used by Alonso et al. [20] . Although ITA involves substantial mathematics, its implementation in practice is fairly straightforward and less computer-intensive than the meta-analytic approach. This is a direct consequence of the fact that the models used in the former are univariate models, which can be fitted using any standard regression software. However, the performance of this approach has not been studied in the mixed continuous and binary endpoint settings. In the next section, insight into the performance of this approach, together with that of the asymptotic interval, is offered through a simulation study.
Fano's inequality and the theoretical plausibility of finding a good surrogate
Fano's inequality shows the relationship between entropy and prediction:
where EPðTÞ ¼ ð1=2eÞe 2hðTÞ . Note that nothing has been assumed about the distribution of our responses and no specific form has been considered for the prediction function g. Also, (22) shows that the predictive quality strongly depends on the characteristics of the endpoint, specifically on its power-entropy. Fano's inequality states that the prediction error increases with EPðTÞ and therefore, if our endpoint has a large power-entropy then a surrogate should produce a large R 2 h to have some predictive value. This means that, for some endpoints, the search for a good surrogate can be a dead end street: the larger the entropy of T the more difficult it is to predict. Studying the the power-entropy before trying to find a surrogate is therefore advisable.
A simulation study
We first lay out the design of the simulation study, whereafter the results are described.
Design of the simulation study
Due to the computational difficulties encountered in practice with the bivariate random-effects models required for the meta-analytic approach by Buyse et al. [10] , ITA becomes an interesting option to consider in practice. However, as stated earlier, the performance of the later has not been investigated in the mixed continuous binary setting, and is the focus of this section. Here, we outline the procedures followed in generating the data used for simulation. The data were generated based on model (1) After generating continuous outcomes based on the above models, a binary surrogate is obtained by dichotomizing the resulting continuous surrogate using the fixed intercept as cut-off point. The dichotomized surrogate takes value 1 if the corresponding continuous surrogate is greater than S and zero otherwise. The above model assumes trial-level and individual-level R 2 values of 0.9 and 0.64, respectively, at the continuous scale. It is important to note that this value of the individuallevel R 2 is the squared correlation between the latent unobservable continuous surrogate endpoint and the observable true endpoints. However, the situation is totally different at the trial-level. Based on (7) and (8), Alonso et al. [20] showed that the relationship between the treatment effects on the latent-continuous and observed-binary surrogate endpoints is linear. Hence, the value of the trial-level R 2 (0.9) is valid both for the latent and observed surrogate.
The number of trials was fixed to either 5, 10, 20, or 30. There were two sets of trial sizes used, the first set consists of 10, 20, 40, or 60, which we term small trial size. The second set consists of 100, 150, 200, or 300, termed large trial size. A full combination of the number of trials and trial sizes was obtained. In each case, 100 runs were performed, assuming either models (11) and (12) or (13) and (14) .
Apart from the primary objectives to investigate the performance of ITA as well as comparing the bootstrap percentile intervals with the asymptotic interval by Alonso and Molenberghs [14] , there are two secondary objectives. The first is to investigate the impact of alternative link functions, at the individual-level, on the performance of ITA. Thus, both probit and logit link functions were implemented in all settings. Second, both linear and nonlinear (splines) functions were considered, at the trial-level, to explore the assumption of linearity between treatment effects. Results are shown for the probit link at the individual-level and linear function at the trial-level. Histograms are used to depict results of the secondary objectives. Table 1 present a selection of the simulation results. Not all simulation settings are shown but we rather focus on both large and small numbers of trials and numbers of subjects per trial. Both individual-level and trial-level R 2 measures are included, as based on (13) and (14) . The tables have columns indicating the number of trials, the trial size, median R 2 , percentile bootstrap and asymptotic 95% confidence intervals.
Simulation results
ITA yields estimates of surrogacy at the individual-level, bounded above by 0.3. Hence, the approach yields estimates substantially lower than the value assumed when generating the data sets, 0.64. This phenomenon is observed in all settings considered in the simulation study. However, it should be noted that the value of 0.64 is the individual-level surrogacy at the latent scale, whereas ITA estimates assess the individual-level surrogacy at the observed scale. Also, it is expected that dichotomizing a continuous variable leads to information loss, which would imply that results obtained from the continuous and discrete version should not generally be expected to be in agreement with each other.
Unlike the individual level, Alonso et al. [24, 27] showed that the trial-level surrogacy at the latent scale translates equally to the observed scale.
For small trial sizes ITA tends to underestimate the trial-level surrogacy. Nevertheless, the models perform considerably well for large trial sizes. The mixed-effect models, (13) and (14) , outperform the fixed-effect models, (11) and (12) , in all simulation settings considered. However, the mixed-models had some convergence issues, which were not encountered with the fixed-effect models. Even so, the percentage of nonconvergence is smaller than 10% within each simulation setting. Generally, increasing the number of trials has little effect on the surrogacy measures, although increasing the trial size appears to yield better estimates for the surrogacy measures. Also, it is not advisable to a use very small number of trials, as it may overestimate or not provide enough data points to reliably assess the trial-level surrogacy.
The 95% asymptotic intervals are tighter than the 95% percentile bootstrap intervals for all simulation settings considered. The discrepancy between these intervals reduces with increases in the number of trials and trial sizes. Further, the choice of an appropriate link function appears to have little influence on the results. Figure 1 shows a plot of magnitude of pooled differences of the triallevel estimates between the logit and probit links, for the fixed-effect models with large sample size. Observe that more than 97% of the samples have differences below 0.1. Also, almost identical results were obtained in each sample when the spline and linear functions were considered at the trial level. This is supported by Figure 1 , as more than 93% of the samples have differences inferior to 0.04.
Analysis of the ARMD data
The case study introduced in section 'The agerelated mocular degeneration study' will now be analyzed. For these data, it is natural to consider center as the unit of analysis, as the data comes from a multi-center trial. There were 36 centers, each treating between 2 and 18 patients. The twostage meta-analytic approach and the corresponding ITA models, described in section 'Validation methods', have been applied to this data set and results displayed in Table 2 . Figure 2 graphically presents the surrogate by true endpoint treatment effect pairs for all centers. The circles are proportional in surface to the trial size, so as to graphically indicate the centers' relative importance.
Extension of the meta-analytic approach to the mixed continuous and binary endpoints, using two-stage fixed-effects model yields R 2 indiv ¼ 0.42 (s.e. 0.13) and R 2 trial ¼ 0.44 (s.e. 0.09). Thus, the loss of at least two lines of vision at 6 months is a relatively poor surrogate for visual acuity at 1 year, a conclusion in synchrony with the one reached by Buyse et al. [10] at the continuous level.
At the individual level, ITA yield estimates of R 2 indiv ranging from 0.2319 to 0.2735. It should be noted that we do not have information about the degree of under-estimation of R 2 indiv by ITA at the observed scaled. As mentioned earlier, research on this issue is still ongoing. Nevertheless, the very low values obtained indicate that the loss of at least two lines of vision at 6 months may not be a good surrogate for visual acuity at 1 year, at the individual level.
ITA yields estimates of R 2 trial ranging from 0.3211 to 0.4864. This indicates that the loss of at least two lines of vision at 6 months does not seem to be a very good surrogate for visual acuity at 1 year, at the trial level. It should be noted that the size of the largest unit of analysis (center) was only 18, though. Thus, there may be a considerable degree of under-estimation on the estimates of R 2 trial . There appears to be no difference between the probit and logit link functions on these data. Also, the line and spline models yield similar results, indicating that the linearity assumption at the trial level may be a plausible one. Furthermore, the mixed models generally have higher estimates for surrogacy measures than the fixed models, hence, exhibiting a lower degree of underestimation.
Discussion
In this article, we reviewed the meta-analytic strategy of Buyse et al. [10] , its extension to mixed binary and continuous endpoints, and the information theoretic approach for validating surrogate endpoints. Combination of the latter with combined-type outcomes is novel. The metaanalytic approach and its extension are mathematically appealing, but encounter practical and/or computational issues. The information theoretic approach involves substantial mathematics yet it is more practically feasible than the meta-analytic approach as it depends on simple univariate models.
The article primarily investigated the performance of the ITA for combined continuous and binary endpoints, particularly continuous surrogate and binary true endpoints, through a simulation study. Generally, this approach underestimates the measures of surrogacy. The underestimation reduces with increase in both the number of trials and trial sizes. However, the simulation study showed that the degree of underestimation is higher with very small trial sizes, even for large number of trials.
The model proposed by Alonso et al. [20] for a general setting, which we referred to as fixed-effects models, was outperformed by its extension to generalized linear mixed models, which we refer to as mixed models. Quite similar results were obtained by extending the linear relationship between the true and surrogate endpoints to nonlinear, spline-based models, at the trial level. Thus, it may be reasonable to assume a linear relationship between the treatment effects on the true and surrogate endpoints.
Asymptotic confidence intervals for surrogacy measures (R 2 indiv and R 2 trial ) developed by Alonso and Molenberghs [14] performed better than bootstrap confidence intervals used by Alonso et al. [20] in the sense of being generally more narrow. On the other hand, the asymptotic confidence intervals are computationally advantageous and are tighter than the bootstrap confidence intervals. Arguably, a fully formal comparison would be of interest; we view this a topic for further research.
The choice of link function appears to have little influence on the estimates of the surrogacy measures. Particularly, the logit and probit link functions gave similar estimates in all settings considered in the simulation study. This is also supported by the fact that these link functions gave almost identical estimates when applied to the motivational case study. These finding are not surprising in view of their well-known relationship.
The meta-analytic strategy for evaluating surrogacy faces computational problems, which are largely alleviated by the information-theoretic approach. On the other hand, the latter may be biased downwards in smaller trials. Therefore, it is advisable to reserve the use of ITA for larger trial sizes. Also, the extended generalized linear mixed models are recommended.
Clearly, the use of validation methods, such as the ones proposed in this article, whether based on R 2 , other association measures, or ITA, is but one component of the broader surrogate endpoint evaluation picture. Clinical and biopharmaceutical arguments will have to be juxtaposed with evidence from the surrogate marker evaluation analysis. Therefore, it is hard to specify a universal cutoff for R 2 -based measures, above which a potential surrogate be deemed 'valid'. Further, once a surrogate has been adopted, or even before, it is important to assess how it will perform in a new trial. Burzykowski and Buyse [25] proposed the so-called surrogate threshold effect (STE). Their method is intended for deriving a sample size large enough for a treatment effect on the surrogate endpoints to translate into a meaningful and significant effect on the true endpoint.
Methods discussed in this article are situated within the meta-analytic framework. This is also true for the recent work by Baker [26] , who proposed the use of average prediction error based on easy-toimplement regression models.
